Understanding patient perspectives and preferences on sildenafil orodispersible formulation: a survey-based evaluation of men using erectile dysfunction medications.
5 affiliations
- 1Section of Endocrinology and Medical Sexology (ENDOSEX), Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
- 2Viatris Inc., Milan, Italy.
- 3Viatris Italia S.R.L., Milan, Italy.
- 4Mylan Pharmaceuticals Pvt Ltd., a Viatris Company, Hyderabad, India.
- 5Deparment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Abstract
Background
Erectile dysfunction (ED) is a common disease condition with major psychosocial and clinical consequences. Over 50% of men aged 40 years and above are estimated to experience some level of ED. Phosphodiesterase type 5 inhibitors (PDE5Is) remain the mainstay of ED treatment. Sildenafil citrate orodispersible film (ODF) is a novel formulation designed to improve convenience and patient satisfaction. This study explored real-world perspectives and patient preferences regarding the use of sildenafil citrate ODF.Methods
A cross-sectional, web-based survey was conducted in Italy (September-November 2024) in adult men using prescription ED medications. Data on demographics, lifestyle, clinical condition, treatment experiences, and patient perceptions about PDE5Is with a focus on sildenafil ODF were collected.Results
The survey included 276 men (mean age 47 years; 43.5% Viagra users, 25% Cialis users, 13.4% other branded ED medication users, and 18.1% generic ED medication users). Most were married (51%), employed (78%), and reported at least one comorbidity (75%), predominantly cardiovascular (53%). Film-coated tablets of PDE5 inhibitors were the most used formulation (72%), while 5% reported sildenafil ODF use.Awareness of sildenafil ODF was high, with valued attributes including water-free administration, portability, discretion, and faster perceived onset of action. Among overall ED medication users, 79% expressed willingness to adopt sildenafil ODF with 33% citing liking of the formulation and 28% citing perceived difference from already using medication. The main barrier to adoption was high cost compared to other ED medications, cited by 37% of the 21% participants who did not express willingness to adopt sildenafil ODF.Conclusion
Sildenafil ODF was widely perceived by patients as a discreet and practical alternative to conventional film-coated tablets, with high willingness for adoption. Aligning treatment choices with patient preferences may enhance adherence, satisfaction, and overall quality of life in ED management.
Related
- The Impasse Model: A Clinical Formulation Framework for Understanding Psychological Impasse and Restoring Movement
- The Ability of Nutrition Warning Labels to Improve Understanding and Choice Outcomes Among Consumers Demonstrating Preferences for Unhealthy Foods
- Extracorporeal kidney support in neonates and infants: therapeutic perspectives and outcomes in multiple organ dysfunction syndrome—a structured narrative review
- Understanding rhythmic behavior in infancy: Perspectives for addressing developmental, methodological, and analytical challenges
- Understanding Patient Perspectives and Acceptability of Integrative Naturopathic Oncology in Metastatic Cancer.
BibTeX
@article{sansone2026understanding,
title = {{Understanding patient perspectives and preferences on sildenafil orodispersible formulation: a survey-based evaluation of men using erectile dysfunction medications.}},
author = {Andrea Sansone and Franco M P Mondello Malvestiti and Raffaella Mantegazza and Shivani Ohri Vignesh and Emmanuele A Jannini and Carmen Ferrara},
journal = {Sexual medicine},
year = {2026},
month = oct,
doi = {10.1093/sexmed/qfag095},
url = {https://europepmc.org/article/MED/42936858},
note = {CC BY-NC},
}
RIS
TY - JOUR
TI - Understanding patient perspectives and preferences on sildenafil orodispersible formulation: a survey-based evaluation of men using erectile dysfunction medications.
AU - Andrea Sansone
AU - Franco M P Mondello Malvestiti
AU - Raffaella Mantegazza
AU - Shivani Ohri Vignesh
AU - Emmanuele A Jannini
AU - Carmen Ferrara
PY - 2026
DA - 2026/10/26
JO - Sexual medicine
DO - 10.1093/sexmed/qfag095
UR - https://europepmc.org/article/MED/42936858
AB - Background Erectile dysfunction (ED) is a common disease condition with major psychosocial and clinical consequences. Over 50% of men aged 40 years and above are estimated to experience some level of ED. Phosphodiesterase type 5 inhibitors (PDE5Is) remain the mainstay of ED treatment. Sildenafil citrate orodispersible film (ODF) is a novel formulation designed to improve convenience and patient satisfaction. This study explored real-world perspectives and patient preferences regarding the use of sildenafil citrate ODF.Methods A cross-sectional, web-based survey was conducted in Italy (September-November 2024) in adult men using prescription ED medications. Data on demographics, lifestyle, clinical condition, treatment experiences, and patient perceptions about PDE5Is with a focus on sildenafil ODF were collected.Results The survey included 276 men (mean age 47 years; 43.5% Viagra users, 25% Cialis users, 13.4% other branded ED medication users, and 18.1% generic ED medication users). Most were married (51%), employed (78%), and reported at least one comorbidity (75%), predominantly cardiovascular (53%). Film-coated tablets of PDE5 inhibitors were the most used formulation (72%), while 5% reported sildenafil ODF use.Awareness of sildenafil ODF was high, with valued attributes including water-free administration, portability, discretion, and faster perceived onset of action. Among overall ED medication users, 79% expressed willingness to adopt sildenafil ODF with 33% citing liking of the formulation and 28% citing perceived difference from already using medication. The main barrier to adoption was high cost compared to other ED medications, cited by 37% of the 21% participants who did not express willingness to adopt sildenafil ODF.Conclusion Sildenafil ODF was widely perceived by patients as a discreet and practical alternative to conventional film-coated tablets, with high willingness for adoption. Aligning treatment choices with patient preferences may enhance adherence, satisfaction, and overall quality of life in ED management.
SN - 2050-1161
ER -